Delaney William E IV 4

4 · ASSEMBLY BIOSCIENCES, INC. · Filed Mar 31, 2026

AI-generated summary of this filing

Updated Mar 31, 2026

Assembly Biosciences (ASMB) CSO William Delaney Receives RSU Award

What Happened

William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences (ASMB), received a grant of 26,000 restricted stock units (RSUs) on March 29, 2026. The grant is reported at $0.00 per share (standard for RSU awards at grant; value will be realized if and when shares vest and are delivered).

Key Details

Transaction date: 2026-03-29; Form 4 filed: 2026-03-31.
Grant: 26,000 RSUs @ $0.00 per share (total reported $0 at grant).
Vesting: RSUs vest in four equal annual installments on March 29 of 2027, 2028, 2029 and 2030 (per footnote F1).
Contingency: The 26,000 RSUs represent 65% of his annual equity grant; the remaining 35% is contingent on stockholder approval to increase the number of shares available under the company’s 2018 Stock Incentive Plan (footnote F2).
Prior holdings note: Filing references 2,909 shares acquired under the company ESPP on May 14, 2025 (footnote F3). Shares owned after this specific award are not specified in the provided excerpt.
Filing timeliness: Form filed two days after the transaction date; no late-filing flag indicated.

Context

RSUs are a form of compensation that convert into actual shares only upon vesting and delivery; this is not an open-market purchase (so it’s not a direct bullish buy signal). The contingent portion tied to shareholder approval means some of the total annual grant depends on a future vote. Grants like this are commonly used for retention and compensation.

Form 4

Period: 2026-03-29

Chief Scientific Officer

Transactions

Footnotes (3)

[F1]Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.
[F2]RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan.
[F3]Includes 2,909 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2025.

Signature

/s/ John O. Gunderson, as Attorney-in-Fact|2026-03-31

1 file